Status:
TERMINATED
Efficacy of Methimazole Dosing Algorithm
Lead Sponsor:
Cook County Health
Conditions:
Graves Disease
Eligibility:
All Genders
18+ years
Brief Summary
To prospectively study the efficacy and safety of the Cook County Health (CCH) methimazole (MMI) dosing algorithm in the setting of new onset Graves' disease.
Detailed Description
To conduct a prospective observational study in 60 patients with newly diagnosed Graves' disease who are either methimazole naive or who have been initiated on MMI within previous 4-6 weeks per CCH al...
Eligibility Criteria
Inclusion
- Non-pregnant adults (\>18 years of age) with new diagnosis of Graves' Disease (elevated free T4, Free T3, low or suppressed TSH, positive TSI and or thyroid eye disease) and
- either drug naïve or who have been initiated on MMI within previous 4-6 weeks per CCH algorithm.
Exclusion
- Pregnant patients
- hyperthyroidism due to other causes, example - Toxic Multinodular Goiter, Iodine induced thyrotoxicosis, etc.
- Graves patients who present with atrial fibrillation, CHF or other end organ damage
Key Trial Info
Start Date :
February 14 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 17 2024
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT05964452
Start Date
February 14 2022
End Date
September 17 2024
Last Update
December 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cook County Health
Chicago, Illinois, United States, 60612